| 席宇菁 才延辉 晋毅 曹钟元 相庚 柴丽清 赵晶 阎爱荣.HER2 阳性乳腺癌转移患者最佳治疗方案的研究进展[J].,2015,15(35):6984-6989 |
| HER2 阳性乳腺癌转移患者最佳治疗方案的研究进展 |
| Progress of Research on the Optimal Treatment for Patients withHER2-positive Metastatic Breast Cancer |
| |
| DOI： |
| 中文关键词: 表皮生长因子受体 乳腺癌转移 靶向治疗 最佳治疗方案 |
| 英文关键词: Human epidermal growth factor receptor 2 (HER2)-positive Metastatic breast cancer Targeted therapy Optimal sequencing
of treatment |
| 基金项目:国家自然科学基金项目（81172149，81372459） |
|
| 摘要点击次数: 1092 |
| 全文下载次数: 0 |
| 中文摘要: |
| 针对人表皮生长因子受体HER2 的靶向制剂曲妥珠单抗，显著改善了HER2 阳性乳腺癌转移患者疾病的发展状况，提高了
患者的总体生存期（OS），然而耐药现象时有发生。其它靶向制剂如帕妥珠单抗，酪氨酸激酶受体抑制剂拉帕替尼和ado-transtusumab
emtansine等克服了其耐药性，为治疗提供了更多选择。这些HER2 靶向制剂单用或联用已显示出良好的临床功效，但最
佳治疗次序依然未知。随着新型靶向制剂的出现，最佳治疗方案的研究成为热点。本篇综述重点阐述了目前HER2 阳性乳腺癌转
移患者最佳治疗方案的研究进展，以及新型靶向制剂的现有状况。 |
| 英文摘要: |
| Trastuzumab, which was the first HER2-directed agent, has significantly improved outcomes for patients with
HER2-positive metastatic breast cancer, however, drug resistance often happened. Other HER2-directed agents such as the pertuzumab,
the tyrosine kinase receptor inhibitor lapatinib, and the immunoconjugate trastuzumab emtansine were developed to overcome resistance
to trastuzumab and provide more options for patients. Recent data based on these HER2-directed agents has shown good clinical efficacy,
but the optimal sequencing of treatments remains unclear. Meanwhile, with the emergence of new HER2-targeted agents, researches
about the optimal sequencing become more and more meaningful. This review focused on the development of researches about the optimal
sequencing and the condition of new HER2-directed agents nowadays. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
